Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 8;14:4757. doi: 10.1038/s41467-023-40489-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a GMT and GMC of SARS-CoV-2 RBD-specific IgG antibodies, and GMT of pseudovirus-neutralizing antibodies to Omicron BA.4/5 on day 0, 14, 28, and 90 in sub-group given CoronaVac (N = 68, 68, 68, 68) or Covilo (N = 32, 32, 32, 31). b–d Seropositive rates (%) (b), seroconversion rates (%) (c), and GMFI (d) of RBD-specific antibodies and pseudovirus-neutralizing antibody 14, 28, and 90 days after booster compared with baseline. Data were shown as Geometric mean ± 95% CI or as box and whiskers in (a), indicating median (middle line), 25th, 75th percentile (box), mean ± 95% CI in (b–d). Seroconversion was defined as at least a 4-fold increase in antibody titers at different time points after booster compared with baseline (day 0). NT50 = 50% neutralization titer. Statistical significance was determined by two-tailed Student’s t-test and one-way ANOVA with Tukey’s multiple comparisons test. P < 0.05 was considered statistically significant and marked with red color. 95% CI: 95% confidence interval, GMT geometric mean titer, GMC geometric mean concentration, GMFI geometric mean fold increase. Source data are provided as a Source Data file.